CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs

Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lixia, Yi, Fei, Fu, Lina, Yang, Jiping, Wang, Si, Wang, Zhaoxia, Suzuki, Keiichiro, Sun, Liang, Xu, Xiuling, Yu, Yang, Qiao, Jie, Belmonte, Juan Carlos Izpisua, Yang, Ze, Yuan, Yun, Qu, Jing, Liu, Guang-Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Higher Education Press 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5413600/
https://www.ncbi.nlm.nih.gov/pubmed/28401346
http://dx.doi.org/10.1007/s13238-017-0397-3
Descripción
Sumario:Amyotrophic lateral sclerosis (ALS) is a complex neurodegenerative disease with cellular and molecular mechanisms yet to be fully described. Mutations in a number of genes including SOD1 and FUS are associated with familial ALS. Here we report the generation of induced pluripotent stem cells (iPSCs) from fibroblasts of familial ALS patients bearing SOD1 (+/A272C) and FUS (+/G1566A) mutations, respectively. We further generated gene corrected ALS iPSCs using CRISPR/Cas9 system. Genome-wide RNA sequencing (RNA-seq) analysis of motor neurons derived from SOD1 (+/A272C) and corrected iPSCs revealed 899 aberrant transcripts. Our work may shed light on discovery of early biomarkers and pathways dysregulated in ALS, as well as provide a basis for novel therapeutic strategies to treat ALS. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13238-017-0397-3) contains supplementary material, which is available to authorized users.

Ejemplares similares